| Dr Samuel Ward Cole, MD | |
|
2610 South Lamar Blvd, Oxford, MS 38655 | |
| (662) 234-1731 | |
| (662) 236-2392 |
| Full Name | Dr Samuel Ward Cole |
|---|---|
| Gender | Male |
| Speciality | Obstetrics/gynecology |
| Experience | 17 Years |
| Location | 2610 South Lamar Blvd, Oxford, Mississippi |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023294527 | NPI | - | NPPES |
| 09483701 | Medicaid | MS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 21544 (Mississippi) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Oxford Clinic For Women Pllc | 0042541435 | 5 |
| Southern Women's Health, Pllc | 2567497985 | 38 |
News Archive
Genetic Immunity, a US/Hungarian biopharmaceutical company developing nanomedicine vaccines, will present data at this week's HIV DART 2010 conference, "Frontiers in Drug Development for Antiretroviral Therapies," in Los Cabos, Mexico. The conference brings international researchers together to discuss the latest developments in the fight against HIV/AIDS.
BELLUS Health Inc. and Celtic Therapeutics announced today that a global confirmatory phase III clinical study was initiated on December 14, 2010 for KIACTA™ (eprodisate). KIACTA™ is a drug candidate being developed for the treatment of AA amyloidosis, a life-threatening orphan disease that occurs in patients with long-lasting inflammatory conditions, most commonly due to rheumatoid arthritis. The study is designed to confirm the safety and efficacy of KIACTA™ in preventing renal function decline in patients with AA amyloidosis.
Each year, millions of people worldwide suffer from potentially fatal infectious diseases that often leave survivors facing a lifetime of related health problems. But what if drugs against such diseases already existed but nobody knew it?
Johnson & Johnson Medical Devices Companies today announced that Acclarent, Inc., a leader in developing minimally-invasive Ear, Nose & Throat technologies, has received clearance from the U.S. Food and Drug Administration to expand the indication for the Acclarent AERA® Eustachian Tube Balloon Dilation System to include its use in patients as young as 18. The device was previously cleared only for adults aged 22 and older.
Mayo Clinic scientists have shown that injections of a hunger hormone blocker in mice can halt the typical weight gain after dieting and help prevent rebound obesity in the long term. The research findings appear in the Proceedings of the National Academy of Sciences.
› Verified 6 days ago
| Entity Name | Womens Pavilion Of South Mississippi Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396795571 PECOS PAC ID: 5799769535 Enrollment ID: O20040726001079 |
News Archive
Genetic Immunity, a US/Hungarian biopharmaceutical company developing nanomedicine vaccines, will present data at this week's HIV DART 2010 conference, "Frontiers in Drug Development for Antiretroviral Therapies," in Los Cabos, Mexico. The conference brings international researchers together to discuss the latest developments in the fight against HIV/AIDS.
BELLUS Health Inc. and Celtic Therapeutics announced today that a global confirmatory phase III clinical study was initiated on December 14, 2010 for KIACTA™ (eprodisate). KIACTA™ is a drug candidate being developed for the treatment of AA amyloidosis, a life-threatening orphan disease that occurs in patients with long-lasting inflammatory conditions, most commonly due to rheumatoid arthritis. The study is designed to confirm the safety and efficacy of KIACTA™ in preventing renal function decline in patients with AA amyloidosis.
Each year, millions of people worldwide suffer from potentially fatal infectious diseases that often leave survivors facing a lifetime of related health problems. But what if drugs against such diseases already existed but nobody knew it?
Johnson & Johnson Medical Devices Companies today announced that Acclarent, Inc., a leader in developing minimally-invasive Ear, Nose & Throat technologies, has received clearance from the U.S. Food and Drug Administration to expand the indication for the Acclarent AERA® Eustachian Tube Balloon Dilation System to include its use in patients as young as 18. The device was previously cleared only for adults aged 22 and older.
Mayo Clinic scientists have shown that injections of a hunger hormone blocker in mice can halt the typical weight gain after dieting and help prevent rebound obesity in the long term. The research findings appear in the Proceedings of the National Academy of Sciences.
› Verified 6 days ago
| Entity Name | Southern Women's Health, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174744379 PECOS PAC ID: 2567497985 Enrollment ID: O20051004000733 |
News Archive
Genetic Immunity, a US/Hungarian biopharmaceutical company developing nanomedicine vaccines, will present data at this week's HIV DART 2010 conference, "Frontiers in Drug Development for Antiretroviral Therapies," in Los Cabos, Mexico. The conference brings international researchers together to discuss the latest developments in the fight against HIV/AIDS.
BELLUS Health Inc. and Celtic Therapeutics announced today that a global confirmatory phase III clinical study was initiated on December 14, 2010 for KIACTA™ (eprodisate). KIACTA™ is a drug candidate being developed for the treatment of AA amyloidosis, a life-threatening orphan disease that occurs in patients with long-lasting inflammatory conditions, most commonly due to rheumatoid arthritis. The study is designed to confirm the safety and efficacy of KIACTA™ in preventing renal function decline in patients with AA amyloidosis.
Each year, millions of people worldwide suffer from potentially fatal infectious diseases that often leave survivors facing a lifetime of related health problems. But what if drugs against such diseases already existed but nobody knew it?
Johnson & Johnson Medical Devices Companies today announced that Acclarent, Inc., a leader in developing minimally-invasive Ear, Nose & Throat technologies, has received clearance from the U.S. Food and Drug Administration to expand the indication for the Acclarent AERA® Eustachian Tube Balloon Dilation System to include its use in patients as young as 18. The device was previously cleared only for adults aged 22 and older.
Mayo Clinic scientists have shown that injections of a hunger hormone blocker in mice can halt the typical weight gain after dieting and help prevent rebound obesity in the long term. The research findings appear in the Proceedings of the National Academy of Sciences.
› Verified 6 days ago
| Entity Name | Oxford Clinic For Women |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508999871 PECOS PAC ID: 6800967324 Enrollment ID: O20080611000217 |
News Archive
Genetic Immunity, a US/Hungarian biopharmaceutical company developing nanomedicine vaccines, will present data at this week's HIV DART 2010 conference, "Frontiers in Drug Development for Antiretroviral Therapies," in Los Cabos, Mexico. The conference brings international researchers together to discuss the latest developments in the fight against HIV/AIDS.
BELLUS Health Inc. and Celtic Therapeutics announced today that a global confirmatory phase III clinical study was initiated on December 14, 2010 for KIACTA™ (eprodisate). KIACTA™ is a drug candidate being developed for the treatment of AA amyloidosis, a life-threatening orphan disease that occurs in patients with long-lasting inflammatory conditions, most commonly due to rheumatoid arthritis. The study is designed to confirm the safety and efficacy of KIACTA™ in preventing renal function decline in patients with AA amyloidosis.
Each year, millions of people worldwide suffer from potentially fatal infectious diseases that often leave survivors facing a lifetime of related health problems. But what if drugs against such diseases already existed but nobody knew it?
Johnson & Johnson Medical Devices Companies today announced that Acclarent, Inc., a leader in developing minimally-invasive Ear, Nose & Throat technologies, has received clearance from the U.S. Food and Drug Administration to expand the indication for the Acclarent AERA® Eustachian Tube Balloon Dilation System to include its use in patients as young as 18. The device was previously cleared only for adults aged 22 and older.
Mayo Clinic scientists have shown that injections of a hunger hormone blocker in mice can halt the typical weight gain after dieting and help prevent rebound obesity in the long term. The research findings appear in the Proceedings of the National Academy of Sciences.
› Verified 6 days ago
| Entity Name | Oxford Clinic For Women Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578105540 PECOS PAC ID: 0042541435 Enrollment ID: O20191016002144 |
News Archive
Genetic Immunity, a US/Hungarian biopharmaceutical company developing nanomedicine vaccines, will present data at this week's HIV DART 2010 conference, "Frontiers in Drug Development for Antiretroviral Therapies," in Los Cabos, Mexico. The conference brings international researchers together to discuss the latest developments in the fight against HIV/AIDS.
BELLUS Health Inc. and Celtic Therapeutics announced today that a global confirmatory phase III clinical study was initiated on December 14, 2010 for KIACTA™ (eprodisate). KIACTA™ is a drug candidate being developed for the treatment of AA amyloidosis, a life-threatening orphan disease that occurs in patients with long-lasting inflammatory conditions, most commonly due to rheumatoid arthritis. The study is designed to confirm the safety and efficacy of KIACTA™ in preventing renal function decline in patients with AA amyloidosis.
Each year, millions of people worldwide suffer from potentially fatal infectious diseases that often leave survivors facing a lifetime of related health problems. But what if drugs against such diseases already existed but nobody knew it?
Johnson & Johnson Medical Devices Companies today announced that Acclarent, Inc., a leader in developing minimally-invasive Ear, Nose & Throat technologies, has received clearance from the U.S. Food and Drug Administration to expand the indication for the Acclarent AERA® Eustachian Tube Balloon Dilation System to include its use in patients as young as 18. The device was previously cleared only for adults aged 22 and older.
Mayo Clinic scientists have shown that injections of a hunger hormone blocker in mice can halt the typical weight gain after dieting and help prevent rebound obesity in the long term. The research findings appear in the Proceedings of the National Academy of Sciences.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Samuel Ward Cole, MD 2610 S Lamar Blvd, Oxford, MS 38655-5243 Ph: (622) 234-1731 | Dr Samuel Ward Cole, MD 2610 South Lamar Blvd, Oxford, MS 38655 Ph: (662) 234-1731 |
News Archive
Genetic Immunity, a US/Hungarian biopharmaceutical company developing nanomedicine vaccines, will present data at this week's HIV DART 2010 conference, "Frontiers in Drug Development for Antiretroviral Therapies," in Los Cabos, Mexico. The conference brings international researchers together to discuss the latest developments in the fight against HIV/AIDS.
BELLUS Health Inc. and Celtic Therapeutics announced today that a global confirmatory phase III clinical study was initiated on December 14, 2010 for KIACTA™ (eprodisate). KIACTA™ is a drug candidate being developed for the treatment of AA amyloidosis, a life-threatening orphan disease that occurs in patients with long-lasting inflammatory conditions, most commonly due to rheumatoid arthritis. The study is designed to confirm the safety and efficacy of KIACTA™ in preventing renal function decline in patients with AA amyloidosis.
Each year, millions of people worldwide suffer from potentially fatal infectious diseases that often leave survivors facing a lifetime of related health problems. But what if drugs against such diseases already existed but nobody knew it?
Johnson & Johnson Medical Devices Companies today announced that Acclarent, Inc., a leader in developing minimally-invasive Ear, Nose & Throat technologies, has received clearance from the U.S. Food and Drug Administration to expand the indication for the Acclarent AERA® Eustachian Tube Balloon Dilation System to include its use in patients as young as 18. The device was previously cleared only for adults aged 22 and older.
Mayo Clinic scientists have shown that injections of a hunger hormone blocker in mice can halt the typical weight gain after dieting and help prevent rebound obesity in the long term. The research findings appear in the Proceedings of the National Academy of Sciences.
› Verified 6 days ago
Dr. Ira Lamar Couey, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 2200 S Lamar Blvd, Oxford, MS 38655 Phone: 662-234-1731 | |
Julie G Harper, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1204 Medical Park Dr, Oxford, MS 38655 Phone: 901-236-5717 Fax: 662-234-4016 | |
Dr. Gregory Orin Patton, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1204 Medical Park Dr, Oxford, MS 38655 Phone: 662-236-5717 Fax: 662-234-4016 | |
Dr. William Elliott Henderson, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2610 S Lamar Blvd, Oxford, MS 38655 Phone: 662-234-1731 Fax: 662-236-2392 | |
Dr. Ronald Blake Smith, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2610 S Lamar Blvd, Oxford, MS 38655 Phone: 662-234-1731 Fax: 662-236-2392 | |
Dr. Marion Glenn Hunt, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1204 Medical Park Dr, Oxford, MS 38655 Phone: 662-236-5717 Fax: 662-234-4016 |